^
    Apply
    TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (NCT05862324)
    Phase 1/2
    Triumvira Immunologics, Inc.
    Active, not recruiting
    Last update posted :
    02/14/2025
    Initiation :
    08/23/2023
    Primary completion :
    08/01/2027
    Completion :
    08/01/2027
    EGFR • HER-2 • BRAF • ALK • CLDN18 • BRCA
    |
    EGFR mutation • BRAF mutation • HER-2 expression • CLDN18.2 positive • ALK translocation • BRCA mutation
    |
    albumin-bound paclitaxel • cyclophosphamide • fludarabine IV • TAC101-Claudin18.2